Drug Development Archives | 第 3 页，共 19 页 | Certara

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

Conference

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Danielle Pillsbury2026 年 3 月 2 日

博客

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026 年 2 月 26 日

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

–

Certara2026 年 2 月 24 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

On-Demand Webinar

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…

Certara2026 年 2 月 23 日

Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara2026 年 2 月 23 日

Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Certara2026 年 2 月 23 日

Blog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026 年 2 月 18 日

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

Certara2026 年 2 月 13 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software